Literature DB >> 18673267

Stem cell implantation for myocardial disorders.

Kenichi Yamahara1, Noritoshi Nagaya.   

Abstract

Cell therapy is currently attracting growing interest as a potential new means of improving the prognosis of patients with heart failure. For practical reasons, autologous skeletal myoblasts have been the first to be tested in clinical trials, but recently cardiovascular researchers has explored many other cell types, including bone marrow cells, endothelial progenitor cells, mesenchymal stem cells, embryonic stem cells, and resident cardiac stem cells. While recent experimental studies and early-phase clinical trials seem to support the concept that cell therapy may enhance cardiac repair, many challenges remain before achieving this goal. Further studies should focus on finding the optimal donor cells for transplantation, the mechanism by which engrafted cells improve cardiac function, controlling the survival and proliferation of transplanted cells, and the development of more efficient cell delivery techniques.

Entities:  

Mesh:

Year:  2008        PMID: 18673267     DOI: 10.2174/156720108784911703

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  3 in total

1.  Controlled delivery of mesenchymal stem cells and growth factors using a nanofiber scaffold for tendon repair.

Authors:  C N Manning; A G Schwartz; W Liu; J Xie; N Havlioglu; S E Sakiyama-Elbert; M J Silva; Y Xia; R H Gelberman; S Thomopoulos
Journal:  Acta Biomater       Date:  2013-02-13       Impact factor: 8.947

Review 2.  Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue.

Authors:  Maritza Mayorga; Amanda Finan; Marc Penn
Journal:  Stem Cell Rev Rep       Date:  2009-01-30       Impact factor: 5.739

3.  A novel (19)F agent for detection and quantification of human dendritic cells using magnetic resonance imaging.

Authors:  Fernando Bonetto; Mangala Srinivas; Arend Heerschap; Robbie Mailliard; Eric T Ahrens; Carl G Figdor; I Jolanda M de Vries
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.